Post by Sartorius

Sartorius marks positive start to 2026: Considerable sales revenue growth and resilient profit margin In the first quarter of 2026, the life science group Sartorius continued to deliver on its positive sales and earnings trajectory in line with expectations. 💬 Sartorius CEO Dr. Michael Grosse said: “Our growth journey continues: Sartorius has started 2026 with substantial sales revenue expansion, driven particularly by significant growth of the recurring consumables business in both divisions. As expected, business with equipment and instruments remains soft but is forecast to improve over the coming quarters of this transition year. At the same time, the lab division is back on a growth path. Our profit margin remained resilient, while we successfully navigated geopolitical tensions, ongoing macroeconomic uncertainty, as well as headwinds from tariffs in the first three months.” ➡️ Group sales revenue up by 7.5 percent ➡️ Bioprocess Solutions Division grows by 8.1 percent ➡️ Lab Products & Services Division returns to robust growth with sales revenue up 4.9 percent ➡️ Profitability remains resilient: Underlying EBITDA margin of 29.7 percent ➡️ Full-year guidance for 2026 confirmed 🔗 Read the full media release: https://lnkd.in/dNAmCVCa